Publicaciones en colaboración con investigadores/as de University of Naples Federico II (16)

2024

  1. Dermatologic immune-related adverse events: It is time for a game change!

    Journal of the European Academy of Dermatology and Venereology

  2. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 128

  3. Supportive oncodermatology practices in Europe and the USA

    Journal of the European Academy of Dermatology and Venereology

2023

  1. Clinical characterization and treatment outcomes of follicular cutaneous immune–related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study

    Journal of the American Academy of Dermatology, Vol. 88, Núm. 3, pp. 718-720

  2. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study

    Cancers, Vol. 15, Núm. 14

2022

  1. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

    British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969

  2. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Journal of the European Academy of Dermatology and Venereology, Vol. 36, Núm. 3, pp. 332-350

  3. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

2019

  1. Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

    JAMA Dermatology, Vol. 155, Núm. 6, pp. 724-728

  2. Clinical Characterization of Immunotherapy-Related Pruritus among Patients Seen in 2 Oncodermatology Clinics

    JAMA Dermatology

  3. Treatment outcomes of immune-related cutaneous adverse events

    Journal of Clinical Oncology, Vol. 37, Núm. 30, pp. 2746-2758

2016

  1. Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts

    Critical Reviews in Oncology/Hematology, Vol. 99, pp. 81-90

2002

  1. Infiltrating lipomas of the face. Reporting five clinical cases

    Anales otorrinolaringológicos ibero-americanos, Vol. 29, Núm. 2, pp. 163-172